ThermoGenesis ($KOOL) now in CLI ! (video)

ThermoGenesis Corp (NASDAQ: KOOL) press released an update on their Res-Q clinical evaluations:

ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference

INITIAL DATA SHOW POSITIVE OUTCOMES IN TREATING CRITICAL LIMB ISCHEMIA AND LONG BONE FRACTURES

What is Res-Q ?  This is a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP). The product is being tested in India in a trial co-sponsored by ThermoGenesis and Totipotent SC, the company's distributor for the Res-Q in India.

The trial has evaluated n=10 of n=15 planned patients with advanced CLI. Safety and AFS (limb salvage) at one year are being evaluated. Secondary endpoints such as ABI (ankle brachial index), six minute walk test, and resting pain are showing good results.

In addition a second trial is evaluating n=16 of n=20 patients with non-union or delayed union fracture of a long bone (tibia) who have undergone composite grafting with autologous bone marrow cell concentrate to evaluate the procedure's safety and effect on fracture healing. Long bone fractures represent an unmet medical need that the med tech companies have been chasing for years. So far the system has shown no intra-operative complications, and one non-device related adverse event. Of nine patients who are now out three-to-six months post-treatment, four have fractures that have united and four have experienced partial unions of the bone fracture which is quite hopeful.

Daily Dose Conclusion: Few are paying attention to KOOL as a therapeutic player in CLI or bone fractures and as a potential challenger to Cytori or even Aastrom or Pluristem in CLI. This is worth watching.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full KOOL chart at Wikinvest

ThermoGenesis Corp (KOOL) - ReOrganizing ?

ThermoGenesis Corp (NASDAQ: KOOL) announced a management transition in conjunction with tactical realignment of company in this press release.

Thermogenesis is an automation/tool's supplier in and around the world of cell therapy. The company has had their struggles with the business model and a run towards profitability which also seems to be a year away. News today that Matthew Plavan (currently CFO / EVP, Business Development), will become CEO and a board member as well as the CFO is tough to read. According to the press release:

• Plavan will replace J. Melville Engle, (who has retired from his position as Chairman and CEO).
• The company will cut eight additional positions and provide additional details on its new operating structure and objectives during its Q2 fiscal 2012 conference call on Thursday, 9-Feb.
• KOOL expects to record one-time expenses of approximately $500,000 related to the reorganization announced in Q3 of fiscal 2012 BUT the restructured operations should result in an annualized expense reduction of approximately $2M (according to KOOL.

Daily Dose Conclusion: No Rush to jump into KOOL on a reorg news but this is a great company, strong technology that at some point could be acquired by a bigger fish.